<DOC>
	<DOCNO>NCT01796457</DOCNO>
	<brief_summary>This ancillary NIDDK-sponsored treatment trial title : Combination Therapy Pegylated Interferon Alfa-2a Tenofovir Versus Tenofovir Monotherapy Chronic Hepatitis B ( NCT01369212 ) Combination Entecavir Peginterferon Therapy HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B ( NCT01369199 ) . This study examine balance immune regulatory effector response hepatitis B-infected participant enrol HBRN 's clinical trial ( NCT01369212 NCT01369199 ) define natural history treatment outcome .</brief_summary>
	<brief_title>HBRN : Immune Regulation Costimulation Natural History Therapeutic Outcome Chronic Hepatitis B</brief_title>
	<detailed_description>Aim 1 . Therapeutic HBV suppression enhance antiviral immune effector response reduce immune inhibitory factor participant chronic hepatitis B . This study also examine antiviral therapy durable effect host immune phenotype define immunological effect interferon-alpha ( IFNÎ± ) therapy chronic HBV participant . Aim 2 . Antiviral immune effector regulatory response , and/or therapy predict long term therapeutic response .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>Ability provide inform consent participation ancillary study Children 18 year age Pregnant woman Participants anemia ( Hgb &lt; 10 Hct &lt; 30 ) Participants active medical condition congestive heart failure chronic lung disease require oxygen , active coronary artery disease unstable angina , sepsis renal failure Participants significant medical condition , autoimmune disease immunosuppression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>Immunology</keyword>
	<keyword>HBV</keyword>
	<keyword>Immune tolerant</keyword>
	<keyword>Immune active</keyword>
</DOC>